Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection
Salma Sheikh-Mohamed,Baweleta Isho,Gary Y. C. Chao,Michelle Zuo,Carmit Cohen,Yaniv Lustig,George R. Nahass,Rachel E. Salomon-Shulman,Grace Blacker,Mahya Fazel-Zarandi,Bhavisha Rathod,Karen Colwill,Alainna Jamal,Zhijie Li,Keelia Quinn de Launay,Alyson Takaoka,Julia Garnham-Takaoka,Anjali Patel,Christine Fahim,Aimee Paterson,Angel Xinliu Li,Nazrana Haq,Shiva Barati,Lois Gilbert,Karen Green,Mohammad Mozafarihashjin,Philip Samaan,Patrick Budylowski,Walter L. Siqueira,Samira Mubareka,Mario Ostrowski,James M. Rini,Olga L. Rojas,Irving L. Weissman,Michal Caspi Tal,Allison McGeer,Gili Regev-Yochay,Sharon Straus,Anne-Claude Gingras,Jennifer L. Gommerman
DOI: https://doi.org/10.1038/s41385-022-00511-0
IF: 9.02
2022-04-25
Mucosal Immunology
Abstract:Mucosal Immunology, Published online: 25 April 2022; doi:10.1038/s41385-022-00511-0Our study finds that a local secretory component-associated IgA response is induced by COVID-19 mRNA vaccination that persists in some, but not all participants. The serum and saliva IgA response modestly correlate at 2–4 weeks post-dose 2. Of note, levels of anti-Spike serum IgA (but not IgG) at this timepoint are lower in participants who subsequently become infected with SARS-CoV-2. As new surges of SARS-CoV-2 variants arise, developing COVID-19 booster shots that provoke high levels of IgA has the potential to reduce person-to-person transmission.
immunology